Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Akero Therapeutics, Inc.
Akero Therapeutics develops a drug candidate called efruxifermin to treat serious liver disease linked to metabolic problems.
Akero Therapeutics is a drug developer focused on a liver disease that has quietly become one of the biggest health problems in rich countries. The disease is often called NASH, and it happens when fat builds up in the liver and the organ becomes inflamed and scarred. It is tied to obesity and type 2 diabetes, and there are still very few good medicines for it. Akero's bet is a single drug candidate called efruxifermin, or EFX, which is designed to mimic a natural hormone in the body that helps control how the liver handles fat and sugar.
The way EFX works is worth a quick detour. Your body makes a hormone called FGF21 that acts a bit like a maintenance crew for the liver and fat tissue. It tells the body to burn fat rather than store it and helps calm inflammation. EFX is an engineered, longer-lasting version of that hormone, given as an injection. The hope is that by turning up this signal, the drug can reduce liver fat, ease inflammation, and stop or even reverse scarring. That scarring is the part that matters most: if it gets bad enough, it can lead to cirrhosis, liver failure, or cancer. Akero is a clinical-stage company, which is a polite way of saying it does not sell anything yet. It earns no revenue from customers; nearly all of its money has come from investors who bought shares and, more recently, from the cash of the large drugmaker that bought it. Its risk is concentrated in one molecule, so every trial result matters enormously. Phase 2 studies showed promising reductions in liver fat and some improvement in scarring scores, but the real test is Phase 3, the large late-stage trials that regulators require before approval. Getting a drug through that gauntlet is expensive and slow, and most candidates fail.
Today Akero is no longer an independent public company. Its shares stopped trading after the Swiss drugmaker Novartis Novartis agreed to buy it in a deal valued around $12 billion, one of the larger bets on a single experimental liver drug. The pitch was simple: Novartis wanted a potential first-in-class treatment for a disease with huge unmet need and few approved options. For a small biotech that had burned through years of cash on a single molecule, the sale is the payoff — and the risk of the Phase 3 trials now sits on Novartis's balance sheet rather than on public shareholders'.
Saved answer · last researched 15 Nov 2026